Development and screening of contrast agents for in vivo imaging of Parkinson's disease

Molecular Imaging and Biology

Volumn 15, Issue 5, 2013, Pages 585-595

  Neal, Krista L ^a   Shakerdge, Naomi B ^a   Hou, Steven S ^a   Klunk, William E ^b   Mathis, Chester A ^b   Nesterov, Evgueni E ^c,e   Swager, Timothy M ^c   McLean, Pamela J ^d   Bacskai, Brian J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d MAYO CLINIC   (United States)

^e LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Alpha Synuclein; Blood brain barrier; Dementia with Lewy bodies; In vivo imaging; Lewy bodies; Lewy Neurites; Molecular imaging; Parkinson's disease; PET

Indexed keywords

3 3' DIETHYLTHIADICARBOCYANINE IODIDE; ALPHA SYNUCLEIN; CONTRAST MEDIUM; HITC; LDS 722; LDS 730; LDS 759; LDS 798; NIAD 1; NILE BLUE 690; NILE RED; ORGANIC COMPOUND; RD 1; STILBENE 420; THK 265; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CORTEX; CELL CULTURE; DRUG BINDING; DRUG PENETRATION; DRUG SCREENING; DRUG SELECTIVITY; DRUG SPECIFICITY; HUMAN; HUMAN TISSUE; LEWY BODY; LEWY NEURITE; LIGAND BINDING; MOLECULAR IMAGING; NERVE CELL; NEURITE; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; TRANSGENIC MOUSE;

MUS MUSCULUS;

ALPHA-SYNUCLEIN; ANIMALS; BACTERIAL PROTEINS; BLOOD-BRAIN BARRIER; CELLS, CULTURED; COMPUTER SYSTEMS; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; HUMANS; LEWY BODIES; LUMINESCENT PROTEINS; MICE; MICE, INBRED C57BL; MOLECULAR IMAGING; PARKINSON DISEASE; PERMEABILITY; STAINING AND LABELING;

EID: 84885313978     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-013-0634-y     Document Type: Article

References (27)

1. de Lau LM, Breteler MM (2006) Epidemiology of Parkinson's disease. Lancet Neurol 5:525-535
2. Stoessl AJ (2012) Neuroimaging in Parkinson's disease: from pathology to diagnosis. Parkinsonism Relat Disord 18(Suppl 1):S55-9
3. Varrone A, Toth M, Steiger C et al (2011) Kinetic analysis and quantification of the dopamine transporter in the nonhuman primate brain with 11C-PE2I and 18F-FE-PE2I. J Nucl Med 52:132-139
4. Sasaki T, Ito H, Kimura Y et al (2012) Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I. J Nucl Med 53:1065-1073
5. Varrone A, Halldin C (2010) Molecular imaging of the dopamine transporter. J Nucl Med 51:1331-1334
6. Hurley MJ, Mash DC, Jenner P (2003) Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT-PCR. Eur J Neurosci 18:2668-2672
7. Bacskai BJ, Hickey GA, Skoch J et al (2003) Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci U S A 100:12462-12467
8. Klunk WE, Engler H, Nordberg A et al (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55:306-319
9. Klunk WE, Engler H, Nordberg A et al (2003) Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. Neuroimaging Clin N Am 13:781-789
10. Klunk WE, Lopresti BJ, Ikonomovic MD et al (2005) Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 25:10598-10606
11. Mathis CA, Mason NS, Lopresti BJ, Klunk WE (2012) Development of positron emission tomography beta-amyloid plaque imaging agents. Semin Nucl Med 42:423-432
12. McKeith IG, Galasko D, Kosaka K et al (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113-1124
13. Cantuti-Castelvetri I, Klucken J, Ingelsson M et al (2005) Alpha-synuclein and chaperones in dementia with Lewy bodies. J Neuropathol Exp Neurol 64:1058-1066
14. Mathis CA, Wang Y, Holt DP et al (2003) Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 46:2740-2754
15. Payton JE, Perrin RJ, Clayton DF, George JM (2001) Protein-protein interactions of alpha-synuclein in brain homogenates and transfected cells. Brain Res Mol Brain Res 95:138-145
16. McLean PJ, Kawamata H, Hyman BT (2001) Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons. Neuroscience 104:901-912
17. Wakabayashi K, Engelender S, Yoshimoto M et al (2000) Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann Neurol 47:521-523
18. Outeiro TF, Putcha P, Tetzlaff JE et al (2008) Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One 3:e1867
19. Danzer KM, Ruf WP, Putcha P et al (2011) Heat-shock protein 70 modulates toxic extracellular alpha-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J 25:326-336
20. Unni VK, Weissman TA, Rockenstein E et al (2010) In vivo imaging of alpha-synuclein in mouse cortex demonstrates stable expression and differential subcellular compartment mobility. PLoS One 5:e10589
21. Rockenstein E, Schwach G, Ingolic E et al (2005) Lysosomal pathology associated with alpha-synuclein accumulation in transgenic models using an eGFP fusion protein. J Neurosci Res 80:247-259
22. Skoch J, Hickey GA, Kajdasz ST et al (2005) In vivo imaging of amyloid-beta deposits in mouse brain with multiphoton microscopy. Methods Mol Biol 299:349-363
23. Spires-Jones TL, de Calignon A, Meyer-Luehmann M et al (2011) Monitoring protein aggregation and toxicity in Alzheimer's disease mouse models using in vivo imaging. Methods 53:201-207
24. Edelstein A, Amodaj N, Hoover K, et al. (2010) Computer control of microscopes using microManager. Curr Protoc Mol Biol Chapter 14:Unit14.20
25. Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9:671-675
26. Swaminathan S, Shen L, Risacher SL et al (2012) Amyloid pathway-based candidate gene analysis of [(11)C]PiB-PET in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. Brain Imaging Behav 6:1-15
27. Dishino DD, Welch MJ, Kilbourn MR, Raichle ME (1983) Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. J Nucl Med 24:1030-1038